Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752888 | 0.94 | ACHE (0.58) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752857 | 0.92 | ACHE (0.68) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752803 | 0.91 | ACHE (0.58) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10943732 | 0.90 | ACHE (0.60) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14387212 | 0.89 | ACHE (0.56) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752945 | 0.86 | ACHE (0.62) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752885 | 0.86 | ACHE (0.62) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752986 | 0.86 | ACHE (0.62) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752825 | 0.85 | ACHE (0.61) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10747649 | 0.84 | ACHE (0.59) | ACHELMNACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088774-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-7888357-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888357-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | CASP2, CASP1, DAPK2 | ACHE 3933/4885LMNA 980/4885CYP3A4 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.